8 citations
,
September 2023 in “Advanced Pharmaceutical Bulletin” In a double-blind clinical trial, this study found that a gel containing chitosan-coated spironolactone nanoparticles effectively reduced acne lesions over 8 weeks without adverse skin effects, suggesting potential for enhanced acne treatment through targeted skin delivery.
18 citations
,
May 2020 in “Biomolecules” This review discusses spironolactone's new roles in tumor immunosurveillance, DNA repair inhibition, and viral infection suppression, highlighting its potential to extend uses beyond traditional applications, but reports no clinical results.
December 2024 in “Pharmaceutics” This review systematically examined recent advancements in spironolactone-loaded nanocarriers, revealing that lipid and vesicular nanoparticles enhance bioavailability and skin penetration for treating androgen-dependent disorders, but highlighted the need for further clinical studies to optimize their use.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.